IQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024.
- Revenue
- +8.00%
- EPS
- +10.2%
- Free cash flow
- −21.3%
- Total debt
- +7.42%
Quarter to September 2026, against a year earlier
Follow IQV
Alert me
IQVIA Holdings Inc. (IQV) valuation and DCF model
At $272.83 the price implies free cash flow after share-based pay growing 12.6% a year for ten years.
Free cash flow after share-based pay grew 16.3% a year over the last ten years, 3.1% over the last five. The price asks for close to its ten-year rate. The industry’s median company is priced for 15.8%.
In December 2017 the price assumed 15.2% a year; IQVIA Holdings Inc. went on to grow free cash flow after share-based pay 18.1% a year to FY2025.
- The price needs
- 12.6% a year for ten years
- $272.83
- today’s price
- Its base case
- 16.3% a year for five years, then 9.8%
- $295.37
- 8.3% above today’s price
Base case on its own ten-year record IQVIA Holdings Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$23.42b 10 years of cash to equity+$40.26b terminal value−$13.65b net debt=$50.04b equity value÷169.40m shares=$295.37 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 31.77× | 30.46× | 59.58× | 47% below | 34.52× | 8% below | |
| P/FCF | 20.96× | 21.64× | 25.92× | 19% below | 33.51× | 37% below | |
| P/B | 6.42× | 6.34× | 5.69× | 13% above | 3.42× | 88% above | |
| EV/EBITDA | 16.54× | 16.17× | 18.33× | 10% below | 23.44× | 29% below | |
| EV/Sales | 3.31× | 3.34× | 3.54× | 7% below | 5.18× | 36% below |
IQV trades at 31.77× P/E, against a 10-year average of 59.58× (range 15.78×–157.66×). That is cheaper than 56% of the last 9 year-end readings; re-rating to the average implies $511.70 per share.